Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605826 · ClinicalTrials.gov registry record · NA
A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence
A NA study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- NA
- Development phase
- 206
- Enrollment target
NCT00605826 is a NA study that has completed, run by Bausch Health Americas. The registered enrollment target is 206 participants.
The verdict
NCT00605826, a NA study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- NA
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used as an injectable bulking agent in the treatment of fecal incontinence. The study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.
Interventions
- DEVICE NASHA/Dx (Solesta) Gel
- DEVICE Sham Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2006-09-07 |
| Est. Completion | 2009-11-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605826
The ClinicalTrials.gov registry entry for NCT00605826 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NASHA/Dx (Solesta) Gel is the first listed.
NCT00605826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605826 about?
NCT00605826 is a clinical study titled "A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence". The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used as an injectable bulking agent in the treatment of fecal incontinence. The study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.
What is the current status of trial NCT00605826?
This trial is currently completed. It is a NA study. The enrollment target is 206 participants. The study started on 2006-09-07. Estimated completion is 2009-11-23.
What interventions are being tested in trial NCT00605826?
The interventions under investigation include: NASHA/Dx (Solesta) Gel (DEVICE), Sham Injection (DEVICE).
Who is sponsoring clinical trial NCT00605826?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.